Compare Merck & Co., Inc. (MRK) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Information Technology Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $133.63 (market cap $321.77B), while Vanguard Information Technology Index Fund ETF trades at $121.85. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Information Technology Index Fund ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| MRK | VGT | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | — |
52-Week High | $131.84 | $125.77 |
52-Week Low | $77.60 | $83.59 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
VGT trades at $121.85, up 1.33% with strong bullish momentum from moving averages. The ETF benefits from institutional accumulation and positive AI infrastructure exposure. Technical indicators show RSI_6 at 82.74 suggesting overbought conditions while ADX signals strong trend strength. Recent news highlights institutional buying sprees and Microsoft's earnings boost to tech ETFs.
Outlook remains positive given institutional confidence and AI-driven growth, though concentration risk and overbought technicals warrant caution. The pure-tech focus has outperformed broader tech ETFs historically, but semiconductor volatility presents near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
